+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Allergy Rhinitis Drugs Market 2024-2028

  • PDF Icon

    Report

  • 165 Pages
  • November 2023
  • Region: Global
  • TechNavio
  • ID: 5007857
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The allergy rhinitis drugs market is forecasted to grow by USD 3.17 bn during 2023-2028, accelerating at a CAGR of 3.92% during the forecast period. The report on the allergy rhinitis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of allergy rhinitis, high unmet medical needs, and technological advances in allergy rhinitis diagnostics.

The allergy rhinitis drugs market is segmented as below:

By Distribution Channel

  • Offline
  • Online

By Product

  • Antihistamines
  • Intranasal corticosteroids
  • Immunotherapies
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the increase in R&D of new therapies as one of the prime reasons driving the allergy rhinitis drugs market growth during the next few years. Also, increasing demand for over-the-counter medicines and an increase in collaborations will lead to sizable demand in the market.

The report on the allergy rhinitis drugs market covers the following areas:

  • Allergy rhinitis drugs market sizing
  • Allergy rhinitis drugs market forecast
  • Allergy rhinitis drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading allergy rhinitis drugs market vendors that include ALK Abello AS, Apotex Inc., Bayer AG, Cadila Pharmaceuticals Ltd., Catalent Inc., Dr Reddys Laboratories Ltd., Faes Farma SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., HAL Allergy BV, Haleon Plc, Hikma Pharmaceuticals Plc, KYORIN Holdings Inc., Merck and Co. Inc., Mitsubishi Chemical Group Corp., Novartis AG, Sanofi SA, Stallergenes Greer Ltd., Ube Corp., and Viatris Inc.. Also, the allergy rhinitis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global allergy rhinitis drugs market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global allergy rhinitis drugs market 2018 - 2022 ($ billion)
4.2 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
4.3 Product Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Distribution Channel
6.1 Market segments
Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%)
6.2 Comparison by Distribution Channel
Exhibit 32: Chart on Comparison by Distribution Channel
Exhibit 33: Data Table on Comparison by Distribution Channel
6.3 Offline - Market size and forecast 2023-2028
Exhibit 34: Chart on Offline - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Offline - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Offline - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Offline - Year-over-year growth 2023-2028 (%)
6.4 Online - Market size and forecast 2023-2028
Exhibit 38: Chart on Online - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Online - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Online - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Online - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Distribution Channel
Exhibit 42: Market opportunity by Distribution Channel ($ billion)
Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ billion)
7 Market Segmentation by Product
7.1 Market segments
Exhibit 44: Chart on Product - Market share 2023-2028 (%)
Exhibit 45: Data Table on Product - Market share 2023-2028 (%)
7.2 Comparison by Product
Exhibit 46: Chart on Comparison by Product
Exhibit 47: Data Table on Comparison by Product
7.3 Antihistamines - Market size and forecast 2023-2028
Exhibit 48: Chart on Antihistamines - Market size and forecast 2023-2028 ($ billion)
Exhibit 49: Data Table on Antihistamines - Market size and forecast 2023-2028 ($ billion)
Exhibit 50: Chart on Antihistamines - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Antihistamines - Year-over-year growth 2023-2028 (%)
7.4 Intranasal corticosteroids - Market size and forecast 2023-2028
Exhibit 52: Chart on Intranasal corticosteroids - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Intranasal corticosteroids - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Intranasal corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Intranasal corticosteroids - Year-over-year growth 2023-2028 (%)
7.5 Immunotherapies - Market size and forecast 2023-2028
Exhibit 56: Chart on Immunotherapies - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Immunotherapies - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Immunotherapies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Immunotherapies - Year-over-year growth 2023-2028 (%)
7.6 Others - Market size and forecast 2023-2028
Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%)
7.7 Market opportunity by Product
Exhibit 64: Market opportunity by Product ($ billion)
Exhibit 65: Data Table on Market opportunity by Product ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 UK - Market size and forecast 2023-2028
Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.10 Japan - Market size and forecast 2023-2028
Exhibit 99: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.11 France - Market size and forecast 2023-2028
Exhibit 103: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on France - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 ALK Abello AS
Exhibit 115: ALK Abello AS - Overview
Exhibit 116: ALK Abello AS - Product / Service
Exhibit 117: ALK Abello AS - Key offerings
12.4 Apotex Inc.
Exhibit 118: Apotex Inc. - Overview
Exhibit 119: Apotex Inc. - Product / Service
Exhibit 120: Apotex Inc. - Key offerings
12.5 Bayer AG
Exhibit 121: Bayer AG - Overview
Exhibit 122: Bayer AG - Business segments
Exhibit 123: Bayer AG - Key news
Exhibit 124: Bayer AG - Key offerings
Exhibit 125: Bayer AG - Segment focus
12.6 Dr Reddys Laboratories Ltd.
Exhibit 126: Dr Reddys Laboratories Ltd. - Overview
Exhibit 127: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 128: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 129: Dr Reddys Laboratories Ltd. - Segment focus
12.7 Faes Farma SA
Exhibit 130: Faes Farma SA - Overview
Exhibit 131: Faes Farma SA - Product / Service
Exhibit 132: Faes Farma SA - Key offerings
12.8 GlaxoSmithKline Plc
Exhibit 133: GlaxoSmithKline Plc - Overview
Exhibit 134: GlaxoSmithKline Plc - Business segments
Exhibit 135: GlaxoSmithKline Plc - Key news
Exhibit 136: GlaxoSmithKline Plc - Key offerings
Exhibit 137: GlaxoSmithKline Plc - Segment focus
12.9 Glenmark Pharmaceuticals Ltd.
Exhibit 138: Glenmark Pharmaceuticals Ltd. - Overview
Exhibit 139: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibit 140: Glenmark Pharmaceuticals Ltd. - Key offerings
12.10 Haleon Plc
Exhibit 141: Haleon Plc - Overview
Exhibit 142: Haleon Plc - Business segments
Exhibit 143: Haleon Plc - Key offerings
Exhibit 144: Haleon Plc - Segment focus
12.11 Hikma Pharmaceuticals Plc
Exhibit 145: Hikma Pharmaceuticals Plc - Overview
Exhibit 146: Hikma Pharmaceuticals Plc - Business segments
Exhibit 147: Hikma Pharmaceuticals Plc - Key offerings
Exhibit 148: Hikma Pharmaceuticals Plc - Segment focus
12.12 Merck and Co. Inc.
Exhibit 149: Merck and Co. Inc. - Overview
Exhibit 150: Merck and Co. Inc. - Business segments
Exhibit 151: Merck and Co. Inc. - Key news
Exhibit 152: Merck and Co. Inc. - Key offerings
Exhibit 153: Merck and Co. Inc. - Segment focus
12.13 Mitsubishi Chemical Group Corp.
Exhibit 154: Mitsubishi Chemical Group Corp. - Overview
Exhibit 155: Mitsubishi Chemical Group Corp. - Business segments
Exhibit 156: Mitsubishi Chemical Group Corp. - Key offerings
Exhibit 157: Mitsubishi Chemical Group Corp. - Segment focus
12.14 Novartis AG
Exhibit 158: Novartis AG - Overview
Exhibit 159: Novartis AG - Business segments
Exhibit 160: Novartis AG - Key offerings
Exhibit 161: Novartis AG - Segment focus
12.15 Sanofi SA
Exhibit 162: Sanofi SA - Overview
Exhibit 163: Sanofi SA - Business segments
Exhibit 164: Sanofi SA - Key news
Exhibit 165: Sanofi SA - Key offerings
Exhibit 166: Sanofi SA - Segment focus
12.16 Stallergenes Greer Ltd.
Exhibit 167: Stallergenes Greer Ltd. - Overview
Exhibit 168: Stallergenes Greer Ltd. - Product / Service
Exhibit 169: Stallergenes Greer Ltd. - Key offerings
12.17 Viatris Inc.
Exhibit 170: Viatris Inc. - Overview
Exhibit 171: Viatris Inc. - Business segments
Exhibit 172: Viatris Inc. - Key news
Exhibit 173: Viatris Inc. - Key offerings
Exhibit 174: Viatris Inc. - Segment focus
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 175: Inclusions checklist
Exhibit 176: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 177: Currency conversion rates for US$
13.4 Research methodology
Exhibit 178: Research methodology
Exhibit 179: Validation techniques employed for market sizing
Exhibit 180: Information sources
13.5 List of abbreviations
Exhibit 181: List of abbreviations
List of Exhibits
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Global Market Characteristics
Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits6: Executive Summary - Chart on Market Segmentation by Product
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size - Data Table on global allergy rhinitis drugs market 2018 - 2022 ($ billion)
Exhibits19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion)
Exhibits20: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
Exhibits23: Five forces analysis - Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition - Five forces 2023 and 2028
Exhibits30: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits31: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Distribution Channel
Exhibits33: Data Table on Comparison by Distribution Channel
Exhibits34: Chart on Offline - Market size and forecast 2023-2028 ($ billion)
Exhibits35: Data Table on Offline - Market size and forecast 2023-2028 ($ billion)
Exhibits36: Chart on Offline - Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Offline - Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Online - Market size and forecast 2023-2028 ($ billion)
Exhibits39: Data Table on Online - Market size and forecast 2023-2028 ($ billion)
Exhibits40: Chart on Online - Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Online - Year-over-year growth 2023-2028 (%)
Exhibits42: Market opportunity by Distribution Channel ($ billion)
Exhibits43: Data Table on Market opportunity by Distribution Channel ($ billion)
Exhibits44: Chart on Product - Market share 2023-2028 (%)
Exhibits45: Data Table on Product - Market share 2023-2028 (%)
Exhibits46: Chart on Comparison by Product
Exhibits47: Data Table on Comparison by Product
Exhibits48: Chart on Antihistamines - Market size and forecast 2023-2028 ($ billion)
Exhibits49: Data Table on Antihistamines - Market size and forecast 2023-2028 ($ billion)
Exhibits50: Chart on Antihistamines - Year-over-year growth 2023-2028 (%)
Exhibits51: Data Table on Antihistamines - Year-over-year growth 2023-2028 (%)
Exhibits52: Chart on Intranasal corticosteroids - Market size and forecast 2023-2028 ($ billion)
Exhibits53: Data Table on Intranasal corticosteroids - Market size and forecast 2023-2028 ($ billion)
Exhibits54: Chart on Intranasal corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Intranasal corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Immunotherapies - Market size and forecast 2023-2028 ($ billion)
Exhibits57: Data Table on Immunotherapies - Market size and forecast 2023-2028 ($ billion)
Exhibits58: Chart on Immunotherapies - Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Immunotherapies - Year-over-year growth 2023-2028 (%)
Exhibits60: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits61: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits62: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits63: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits64: Market opportunity by Product ($ billion)
Exhibits65: Data Table on Market opportunity by Product ($ billion)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibits88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibits89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits92: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits96: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits100: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibits101: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits103: Chart on France - Market size and forecast 2023-2028 ($ billion)
Exhibits104: Data Table on France - Market size and forecast 2023-2028 ($ billion)
Exhibits105: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibits106: Data Table on France - Year-over-year growth 2023-2028 (%)
Exhibits107: Market opportunity By Geographical Landscape ($ billion)
Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibits109: Impact of drivers and challenges in 2023 and 2028
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: ALK Abello AS - Overview
Exhibits116: ALK Abello AS - Product / Service
Exhibits117: ALK Abello AS - Key offerings
Exhibits118: Apotex Inc. - Overview
Exhibits119: Apotex Inc. - Product / Service
Exhibits120: Apotex Inc. - Key offerings
Exhibits121: Bayer AG - Overview
Exhibits122: Bayer AG - Business segments
Exhibits123: Bayer AG - Key news
Exhibits124: Bayer AG - Key offerings
Exhibits125: Bayer AG - Segment focus
Exhibits126: Dr Reddys Laboratories Ltd. - Overview
Exhibits127: Dr Reddys Laboratories Ltd. - Business segments
Exhibits128: Dr Reddys Laboratories Ltd. - Key offerings
Exhibits129: Dr Reddys Laboratories Ltd. - Segment focus
Exhibits130: Faes Farma SA - Overview
Exhibits131: Faes Farma SA - Product / Service
Exhibits132: Faes Farma SA - Key offerings
Exhibits133: GlaxoSmithKline Plc - Overview
Exhibits134: GlaxoSmithKline Plc - Business segments
Exhibits135: GlaxoSmithKline Plc - Key news
Exhibits136: GlaxoSmithKline Plc - Key offerings
Exhibits137: GlaxoSmithKline Plc - Segment focus
Exhibits138: Glenmark Pharmaceuticals Ltd. - Overview
Exhibits139: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibits140: Glenmark Pharmaceuticals Ltd. - Key offerings
Exhibits141: Haleon Plc - Overview
Exhibits142: Haleon Plc - Business segments
Exhibits143: Haleon Plc - Key offerings
Exhibits144: Haleon Plc - Segment focus
Exhibits145: Hikma Pharmaceuticals Plc - Overview
Exhibits146: Hikma Pharmaceuticals Plc - Business segments
Exhibits147: Hikma Pharmaceuticals Plc - Key offerings
Exhibits148: Hikma Pharmaceuticals Plc - Segment focus
Exhibits149: Merck and Co. Inc. - Overview
Exhibits150: Merck and Co. Inc. - Business segments
Exhibits151: Merck and Co. Inc. - Key news
Exhibits152: Merck and Co. Inc. - Key offerings
Exhibits153: Merck and Co. Inc. - Segment focus
Exhibits154: Mitsubishi Chemical Group Corp. - Overview
Exhibits155: Mitsubishi Chemical Group Corp. - Business segments
Exhibits156: Mitsubishi Chemical Group Corp. - Key offerings
Exhibits157: Mitsubishi Chemical Group Corp. - Segment focus
Exhibits158: Novartis AG - Overview
Exhibits159: Novartis AG - Business segments
Exhibits160: Novartis AG - Key offerings
Exhibits161: Novartis AG - Segment focus
Exhibits162: Sanofi SA - Overview
Exhibits163: Sanofi SA - Business segments
Exhibits164: Sanofi SA - Key news
Exhibits165: Sanofi SA - Key offerings
Exhibits166: Sanofi SA - Segment focus
Exhibits167: Stallergenes Greer Ltd. - Overview
Exhibits168: Stallergenes Greer Ltd. - Product / Service
Exhibits169: Stallergenes Greer Ltd. - Key offerings
Exhibits170: Viatris Inc. - Overview
Exhibits171: Viatris Inc. - Business segments
Exhibits172: Viatris Inc. - Key news
Exhibits173: Viatris Inc. - Key offerings
Exhibits174: Viatris Inc. - Segment focus
Exhibits175: Inclusions checklist
Exhibits176: Exclusions checklist
Exhibits177: Currency conversion rates for US$
Exhibits178: Research methodology
Exhibits179: Validation techniques employed for market sizing
Exhibits180: Information sources
Exhibits181: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global allergy rhinitis drugs market: ALK Abello AS, Apotex Inc., Bayer AG, Cadila Pharmaceuticals Ltd., Catalent Inc., Dr Reddys Laboratories Ltd., Faes Farma SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., HAL Allergy BV, Haleon Plc, Hikma Pharmaceuticals Plc, KYORIN Holdings Inc., Merck and Co. Inc., Mitsubishi Chemical Group Corp., Novartis AG, Sanofi SA, Stallergenes Greer Ltd., Ube Corp., and Viatris Inc..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increase in R and D of new therapies.'

According to the report, one of the major drivers for this market is the increasing prevalence of allergy rhinitis.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ALK Abello AS
  • Apotex Inc.
  • Bayer AG
  • Cadila Pharmaceuticals Ltd.
  • Catalent Inc.
  • Dr Reddys Laboratories Ltd.
  • Faes Farma SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • HAL Allergy BV
  • Haleon Plc
  • Hikma Pharmaceuticals Plc
  • KYORIN Holdings Inc.
  • Merck and Co. Inc.
  • Mitsubishi Chemical Group Corp.
  • Novartis AG
  • Sanofi SA
  • Stallergenes Greer Ltd.
  • Ube Corp.
  • Viatris Inc.